Cited by 397Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 94 of the 101 references it cites were found in a registry or an index.

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:

Open access

Grossberg, George T·2003·Current Therapeutic Research

DOI 10.1016/s0011-393x(03)00059-6PMC PMC4052996

Open this paper in CoChat — free account Open PDF

Abstract

Background Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. In addition to differences in selectivity for AChE and BuChE, ChE inhibitors also differ in pharmacokinetic and pharmacodynamic properties, and these differences could significantly impact on safety, tolerability, and efficacy.Objective The aim of this article was to provide an overview of the ChE inhibitors widely used in AD, focusing on key pharmacologic differences among agents and how these may translate into important differences in safety, tolerability, and efficacy in clinical practice.Methods Using published literature collected over time by the author, a review was conducted, focusing on the pharmacology and clinical data of donepezil, galantamine, and rivastigmine.Results All ChE inhibitors have the potential to induce centrally mediated cholinergic adverse events (AEs), such as nausea and vomiting, if the dose is increased too rapidly or in increments that are too large. These AEs, which are most likely to occur during the "getting on," or dose-escalation, phase of treatment, may result in patients discontinuing treatment early without achieving optimum therapeutic benefit. To reduce the incidence of these AEs, a slow dose-escalation schedule has been established in clinical practice, consisting of a "start low, go slow" procedure with a minimum of 4 weeks between dose increases. After "getting on" treatment, maintaining treatment in the long term, or "staying on," may be achieved with good safety, tolerability, and sustained symptomatic efficacy across the key symptom domains (activities of daily living, behavior, and cognition).Conclusions ChE inhibitors provide symptomatic benefit in AD across key symptom domains. Factors influencing the safety, tolerability, and efficacy of these agents in clinical practice include ChE enzymes inhibited, brain and brain-region ChE selectivity, and metabolism route. Class-specific cholinergic AEs can be minimized using slow, flexible dose escalation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0011-393x(03)00059-6

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
J Neuropsychiatry Clin Neurosci
Yudofsky, S. C., & Hales, R. E. (1992) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.4.4.359 · Cited by 3,818
Physicians Desk Reference
Arky, R. A. (1994) · Cited by 2,632
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Molecular and cellular biology of cholinesterases
Massoulié, J., Pezzementi, L., Bon, S., Krejci, E., & Vallette, F.-M. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90040-y · Cited by 1,214
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme
Inestrosa, N. C., Alvarez, A. R., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C. A., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,117

Show all 101 references

Research works printed but not linked: 10

McRae, 1999, A large-scale, open-label trial of donepezil in the treatment of Alzheimer's disease: Side effects and concomitant medication use, Int J Neuropharmacol, 2, S176
Shua-Haim, 2001, Safety and tolerability of slow titration of rivastigmine (Exelon) in the treatment of patients with Alzheimer's disease (AD): An overall analysis of two prospective studies, J Am Geriatr Soc, 49, S76
Vellas, 1998, Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients, Int J Geriatr Psychopharmacol, 1, 140
Schneider, 1998, Systematic review of efficacy of rivastigmine for patients with Alzheimer's disease, Int J Geriatr Psychopharmacol, 1, S26
Anand, 2000, Dose-response effect of rivastigmine in the treatment of Alzheimer's disease, Int J Geriatr Psychopharmacol, 2, 68
Cummings, 2000, Rivastigmine provides behavioural benefits to Alzheimer's disease patients residing in a nursing home: Findings from a 26-week trial, Neurology, 54, A468
Sanders, 2001, Donepezil in dementia with Lewy bodies: Treatment and withdrawal, Int Psychogeriatr, 13, 224
Raskind M, Truyen L. Galantamine has long-term cognitive benefits in Alzheimer's disease—an analysis of responder rates at 36 months. Poster presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy; April 3–6, 2003; Geneva, Switzerland.
Grossberg, 2001, Rivastigmine in Alzheimer's disease: Efficacy over 2 years compared with historical controls, Int Psychogeriatr, 13, 237
Barber, 1996, Butyrylcholinesterase alters the aggregation state of Aβ amyloid, Proc Soc Neurosci, 22, 1172

Sorted by citations

Items 101–200 of 397

Disease‐modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil
Vasilopoulou, F., Rodríguez‐Arévalo, S., Bagán, A., Escolano, C., Griñán‐Ferré, C., & Pallàs, M. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15478 · Cited by 29
Evaluation of multifunctional synthetic tetralone derivatives for treatment of Alzheimer's disease
Leng, J., Qin, H., Zhu, K., Jantan, I., Hussain, M. A., Sher, M., Amjad, M. W., Hassan, M. N. U., Ahmad, W., & Bukhari, S. N. A. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12822 · Cited by 29
Scope of β-Secretase (BACE1)-Targeted Therapy in Alzheimer’s Disease: Emphasizing the Flavonoid Based Natural Scaffold for BACE1 Inhibition
Das, S., Sengupta, S., & Chakraborty, S. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00579 · Cited by 27
In Silico Design of Dual-Binding Site Anti-Cholinesterase Phytochemical Heterodimers as Treatment Options for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., Ahmed, A., & Carter, W. G. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb44010012 · Cited by 28
Disruption of hippocampal neuronal circuit function depends upon behavioral state in the APP/PS1 mouse model of Alzheimer’s disease
Zhou, H., Li, H., Gowravaram, N., Quan, M., Kausar, N., & Gomperts, S. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-25364-2 · Cited by 29
Long-Term Supplementation of Syzygium cumini (L.) Skeels Concentrate Alleviates Age-Related Cognitive Deficit and Oxidative Damage: A Comparative Study of Young vs. Old Mice
Malik, N., Javaid, S., Ashraf, W., Siddique, F., Rasool, M. F., Alqahtani, F., Ahmad, T., Abrar, M. A., & Imran, I. (2023) · Nutrients · doi:10.3390/nu15030666 · Cited by 28
Morphology‐based mammalian stem cell tests reveal potential developmental toxicity of donepezil
Lau, C. G. Y., & Marikawa, Y. (2014) · Molecular Reproduction and Development · doi:10.1002/mrd.22423 · Cited by 28
Alzheimer's Disease: A Review of Pathology, Current Treatments, and the Potential Therapeutic Effect of Decreasing Oxidative Stress by Combined Vitamin D and l -Cysteine Supplementation
Jain, S. K., Stevens, C. M., Margret, J. J., & Levine, S. N. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0245 · Cited by 33
A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides
Singh, K., Gupta, J. K., Kumar, S., & Soni, U. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037275221240327042353 · Cited by 32
Phytochemicals from Dodonaea viscosa and their antioxidant and anticholinesterase activities with structure–activity relationships
Muhammad, A., Tel‐Çayan, G., Öztürk, M., Duru, M. E., Nadeem, S., Anis, I., Ng, S. W., & Shah, M. R. (2016) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1113992 · Cited by 27
Metformin and its sulphonamide derivative simultaneously potentiateanti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation
Markowicz-Piasecka, M., Huttunen, K. M., & Sikora, J. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1499627 · Cited by 27
Multidirectional insights on Chrysophyllum perpulchrum leaves and stem bark extracts: HPLC-ESI-MSn profiles, antioxidant, enzyme inhibitory, antimicrobial and cytotoxic properties
Baloğlu, M. C., Llorent-Martínez, E. J., Aumeeruddy, M. Z., Mahomoodally, M. F., Altunoğlu, Y. Ç., Ustaoglu, B., Öçal, M., Gürel, S., Béné, K., Sinan, K. I., et al. (2019) · Industrial Crops and Products · doi:10.1016/j.indcrop.2019.03.066 · Cited by 27
Repeated administration of a selenium-containing indolyl compound attenuates behavioural alterations by streptozotocin through modulation of oxidative stress in mice
Bampi, S. R., Casaril, A. M., Sousa, F. S. S., Pesarico, A. P., Vieira, B. M., Lenardao, E. J., & Savegnago, L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.06.006 · Cited by 27
Natural Bioactive Compounds from Macroalgae and Microalgae for the Treatment of Alzheimer’s Disease: A Review
Jy, L., Wong, C.-Y., Koh, R. Y., Lim, C. L., Kok, Y.-Y., & Chye, S. M. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/jnkb9714 · Cited by 26
Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease
Inamdar, A., Gurupadayya, B., Halagali, P., Nandakumar, S., Pathak, R., Singh, H., & Sharma, H. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128344571241018154506 · Cited by 33
Chromatographic Fingerprint Analysis, Acetylcholinesterase Inhibitory Properties and Antioxidant Activities of Redflower Ragleaf (C rassocephalum Crepidioides) Extract
Adefegha, S. A., Oboh, G., Molehin, O. R., Saliu, J. A., Athayde, M. L., & Boligon, A. A. (2015) · Journal of Food Biochemistry · doi:10.1111/jfbc.12200 · Cited by 26
Flow-through enzyme immobilized amperometric detector for the rapid screening of acetylcholinesterase inhibitors by flow injection analysis
Vandeput, M., Parsajoo, C., Vanheuverzwijn, J., Patris, S., Yardım, Y., le Jeune, A., Sarakbi, A., Mertens, D., & Kauffmann, J. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.09.012 · Cited by 28
Synthesis and cholinesterase inhibiting potential of A-ring azepano- and 3-amino-3,4-seco-triterpenoids
Kazakova, O. B., Smirnova, I. E., Lopatina, T. V., Giniyatullina, G. V., Petrova, A. V., Khusnutdinova, E. F., Csük, R., Serbian, I., & Loesche, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104001 · Cited by 26
Long-acting injectable donepezil microspheres: Formulation development and evaluation
Choi, G.-W., Lee, S., Kang, D. W., Kim, J. H., Kim, J. H., & Cho, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.022 · Cited by 26
Chemical profiling of edible seaweed (Ochrophyta) extracts and assessment of their in vitro effects on cell-free enzyme systems and on the viability of glutamate-injured SH-SY5Y cells
Fernandes, F., Barbosa, M., Pereira, D. M., Sousa‐Pinto, I., Valentão, P., Azevedo, I. C., & Andrade, P. B. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.04.033 · Cited by 25
Ultrasound-Assisted Extraction of Isoquercetin from Ephedra alata (Decne): Optimization Using Response Surface Methodology and In Vitro Bioactivities
Maaiden, E. E., Qarah, N., Ezzariai, A., Mazar, A., Nasser, B., Moustaid, K., Boukcim, H., Hirich, A., Kouisni, L., & Kharrassi, Y. E. (2023) · Antioxidants · doi:10.3390/antiox12030725 · Cited by 25
Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors
Chierrito, T. P. C., Mantoani, S. P., Roca, C., Sebastián-Pérez, V., Martínez‐González, L., Pérez, D. I., Pérez, C., Canales, Á., Cañada, F. J., Campillo, N. E., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.007 · Cited by 24
Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review)
Hassan, M., Abbas, Q., Seo, S., Shahzadi, S., Alashwal, H., Zaki, N., Iqbal, Z., & Moustafa, A. A. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9044 · Cited by 24
Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer’s Disease
Castañeda, A., Ferraz, R., Vieira, M., Cardoso, I., Vasconcelos, V. M., & Martins, R. F. (2021) · Marine Drugs · doi:10.3390/md19060343 · Cited by 25
Bio-guided isolation of cholinesterase inhibitors from the bulbs of
Kissling, J., Ioset, J., Marston, A., & Hostettmann, K. (2005) · Phytotherapy Research · doi:10.1002/ptr.1770 · Cited by 24
Fatty Acid Composition, Antioxidant, Anticholinesterase and Tyrosinase Inhibitory Activities of Four Serratula Species from Anatolia
Tel‐Çayan, G., Öztürk, M., Duru, M. E., Doğan, B., & Harmandar, M. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.5072/zenodo.24596 · Cited by 24
Synthesis and Anticholinesterase Activity and Cytotoxicity of Novel Amide Derivatives
Altıntop, M. D., Kaplancıklı, Z. A., Özdemır, A., Turan‐Zitouni, G., Temel, H. E., & Akalın, G. (2011) · Archiv der Pharmazie · doi:10.1002/ardp.201100124 · Cited by 23
Synthesis and screening for acetylcholinesterase inhibitor activity of some novel 2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-ones: Derivatives of irbesartan key intermediate
KAVITHA, C. V., Gaonkar, S. L., Chandra, J. N. N. S., Sadashiva, C. T., & Rangappa, K. S. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.07.014 · Cited by 23
Inhibition of BACE1, MAO‐B, cholinesterase enzymes, and anti‐amyloidogenic potential of selected natural phytoconstituents: Multi‐target‐directed ligand approach
Chowdhury, S., & Kumar, S. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13571 · Cited by 22
Corpus callosum anatomical changes in Alzheimer patients and the effect of acetylcholinesterase inhibitors on corpus callosum morphometry
Khasawneh, R. R., Abu‐El‐Rub, E., Alzu’bi, A., Abdelhady, G. T., & Al-Soudi, H. S. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269082 · Cited by 22
In vitro biological studies and computational prediction-based analyses of pyrazolo[1,5- a ]pyrimidine derivatives
Almehizia, A. A., Aboulthana, W. M., Naglah, A. M., & Hassan, A. S. (2024) · RSC Advances · doi:10.1039/d4ra00423j · Cited by 22
Network pharmacology-based approach to elucidate the pharmacologic mechanisms of natural compounds from Dictyostelium discoideum for Alzheimer's disease treatment
Patil, N., Dhariwal, R., Mohammed, A., Wei, L. S., & Jain, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28852 · Cited by 24
Anti-Amyloid Aggregation Activity of Black Sesame Pigment: Toward a Novel Alzheimer’s Disease Preventive Agent
Panzella, L., Eidenberger, T., & Napolitano, A. (2018) · Molecules · doi:10.3390/molecules23030676 · Cited by 22
Influence of Physician Sex and Gender on Prescribing Practices Among Older Adults
Mishra, A., Read, S. H., & Rochon, P. A. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16851 · Cited by 21
Dialkyl phenyl phosphates as novel selective inhibitors of butyrylcholinesterase
Law, K.-S., Acey, R. A., Smith, C. R., Benton, D., Soroushian, S., Eckenrod, B., Stedman, R., Kantardjieff, K. A., & Nakayama, K. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.186 · Cited by 21
Health impact of the commercially cultivated mushroom Agaricus bisporus and wild-growing mushroom Ganoderma resinaceum - a comparative overview
Kozarski, M., Klaus, A. S., Vunduk, J., Jakovljević, D. M., Jadranin, M. B., & Nikšić, M. (2019) · Journal of the Serbian Chemical Society · doi:10.2298/jsc190930129k · Cited by 21
Histamine H3 receptor and cholinesterases as synergistic targets for cognitive decline: Strategies to the rational design of multitarget ligands
Lopes, F. B., Aranha, C. M. S. Q., & Fernandes, J. P. S. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13866 · Cited by 22
Associations of the Lipidome with Ageing, Cognitive Decline and Exercise Behaviours
Kadyrov, M., Whiley, L., Brown, B. M., Erickson, K. I., & Holmes, E. C. (2022) · Metabolites · doi:10.3390/metabo12090822 · Cited by 25
Edible Seaweeds Extracts: Characterization and Functional Properties for Health Conditions
Coelho, M., Duarte, A. P., Pinto, S., Botelho, H. M., Reis, C. P., Serralheiro, M. L., & Pacheco, R. (2023) · Antioxidants · doi:10.3390/antiox12030684 · Cited by 22
Proarrhythmic Effect of Acetylcholine-Esterase Inhibitors Used in the Treatment of Alzheimer’s Disease: Benefit of Rivastigmine in an Experimental Whole-Heart Model
Ellermann, C., Coenen, A., Niehues, P., Leitz, P. R., Kochhäuser, S., Dechering, D. G., Fehr, M., Eckardt, L., & Frommeyer, G. (2019) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09543-8 · Cited by 19
Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson’s and Alzheimer’s Disease
Keighron, C. N., Avazzadeh, S., Goljanek‐Whysall, K., McDonagh, B., Howard, L., Ritter, T., & Quinlan, L. R. (2023) · Biomedicines · doi:10.3390/biomedicines11030728 · Cited by 22
Discovery of Multitarget-Directed Ligands from Piperidine Alkaloid Piperine as a Cap Group for the Management of Alzheimer’s Disease
Bhanukiran, K., Singh, S. K., Singh, R., Kumar, A., & Hemalatha, S. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00269 · Cited by 19
Microalgae and cyanobacteria as natural sources of antioxidant enzymes and enzyme inhibitors for Alzheimer's and diabetes
Odenthal, K., Nunes, E. B., Nunes, N., Fernandes, T., Fernandes, I. A., & de Carvalho, M. Â. A. P. (2024) · Algal Research · doi:10.1016/j.algal.2024.103610 · Cited by 19
Novel 12-hydroxydehydroabietylamine derivatives act as potent and selective butyrylcholinesterase inhibitors
Loesche, A., Wiemann, J., Rohmer, M., Brandt, W., & Csük, R. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103092 · Cited by 19
Automated Method, Based on Micro-Sequential Injection, for the Study of Enzyme Kinetics and Inhibition
Chen, Y., Carroll, A. D., Scampavia, L. D., & Růžička, J. (2006) · Analytical Sciences · doi:10.2116/analsci.22.9 · Cited by 19
Cholinesterase inhibitory potential of Dillenia suffruticosa chemical constituents and protective effect against Aβ−induced toxicity in transgenic Caenorhabditis elegans model
Abubakar, S., Khor, B., Khaw, K. Y., Murugaiyah, V., & Chan, K. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100022 · Cited by 18
Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration
Sen, D., Rathee, S., Pandey, V., Jain, S., & Patil, U. K. (2024) · Current Alzheimer Research · doi:10.2174/0115672050309057240404075003 · Cited by 19
Effects of phenothiazine-structured compounds on APP processing in Alzheimer's disease cellular model
Yuksel, M., Biberoğlu, K., Önder, S., AKBULUT, K. G., & Tacal, Ö. (2017) · Biochimie · doi:10.1016/j.biochi.2017.04.012 · Cited by 19
In Vitro Screening for Antioxidant and Anticholinesterase Effects of Uvaria littoralis Blume.: A Nootropic Phytotherapeutic Remedy
Rahman, A., Haque, A., Uddin, M. S., Mian, M. M., Sufian, M. A., Rahman, M. M., Ali, Y. M., Rafe, M. R., Abdel‐Daim, M. M., Uddin, M. J., et al. (2017) · Journal of Intellectual Disability - Diagnosis and Treatment · doi:10.6000/2292-2598.2017.05.02.3 · Cited by 18
Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation
Yehia, S. A., Elshafeey, A. H., & Elsayed, I. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01530.x · Cited by 18
High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies.
Amini, H., & Ahmadiani, A. (2010) · Europe PMC (PubMed Central) · Cited by 18
Central Administration of Ampelopsin A Isolated from Vitis vinifera Ameliorates Cognitive and Memory Function in a Scopolamine-Induced Dementia Model
Hong, Y., Choi, Y., Han, Y., Oh, S., Lee, A., Lee, B., Magnan, R., Ryu, S. Y., Choi, C. W., & Kim, M. S. (2021) · Antioxidants · doi:10.3390/antiox10060835 · Cited by 17
A Mild Dose of Aspirin Promotes Hippocampal Neurogenesis and Working Memory in Experimental Ageing Mice
Andrews, J. F. V., Selvaraj, D. B., Kumar, A., Roshan, S. A., Anusuyadevi, M., & Kandasamy, M. (2023) · Brain Sciences · doi:10.3390/brainsci13071108 · Cited by 17
A Systematic Review on Drugs Acting as Nicotinic Acetylcholine Receptor Agonists in the Treatment of Dementia
Crestini, A., Carbone, E., Rivabene, R., Ancidoni, A., Rosa, P., Tata, A. M., Fabrizi, E., Locuratolo, N., Vanacore, N., Lacorte, E., et al. (2024) · Cells · doi:10.3390/cells13030237 · Cited by 20
Design, Synthesis, and Biological Evaluation of Ferulic Acid Template-Based Novel Multifunctional Ligands Targeting NLRP3 Inflammasome for the Management of Alzheimer’s Disease
Singh, G., Shankar, G., Panda, S. R., Kumar, S., Rai, S., Verma, H., Kumar, P., Nayak, P. K., Naidu, V. G. M., Srikrishna, S., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00679 · Cited by 17
Crystal structure, phytochemical study and enzyme inhibition activity of Ajaconine and Delectinine
Ahmad, S., Ahmad, H., Khan, H. U., Shahzad, A., Khan, E., Shah, S. A. A., Ali, M., Wadud, A., Ghufran, M., Naz, H., et al. (2016) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2016.06.051 · Cited by 17
Prevalence of and risk factors for adverse events in Alzheimer’s patients receiving anti-dementia drugs in at-home care
Imai, H., Hirai, T., Kumazawa, R., Nakagawa, S., Yonezawa, A., Matsubara, K., & Nakao, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231226 · Cited by 16
Strategies to improve tolerability of rivastigmine: a case series
Venkatesh, K., Bullock, R. M., & Akbaş, A. N. B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x162791 · Cited by 17
Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease
Yuksel, M., Biberoğlu, K., Önder, S., AKBULUT, K. G., & Tacal, Ö. (2017) · Biochimie · doi:10.1016/j.biochi.2017.12.004 · Cited by 17
Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease Dementia
Frost, E. D., Shi, S. X., Byroju, V. V., Rissardo, J. P., Donlon, J., Vigilante, N. F., Murray, B. P., Walker, I. M., McGarry, A. J., Ferraro, T. N., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14121163 · Cited by 17
Recent Advances in the Search for Effective Anti-Alzheimer’s Drugs
Ogoś, M., Stary, D., & Bajda, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010157 · Cited by 17
Therapeutic potential of hydrogen-rich water in zebrafish model of Alzheimer’s disease: targeting oxidative stress, inflammation, and the gut-brain axis
He, J., Xu, P., Xu, T., Yu, H., Wang, L., Chen, R., Zhang, K., Yao, Y., Xie, Y., Yang, Q., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1515092 · Cited by 17
Antioxidant, anti-cholinesterase and antibacterial activities of the bark extracts of Garcinia hombroniana
Jamila, N. (2013) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp12.944 · Cited by 16
Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer’s disease
Kuroda, A., Setoguchi, M., Uchino, Y., Nagata, K., & Hokonohara, D. (2018) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13275 · Cited by 16
Rivastigmine Transdermal Patch
Yang, L. P. H., & Keating, G. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00007 · Cited by 16
A Review on Phyto-Therapeutic Approaches in Alzheimer’s Disease
Sahiner, M., Yilmaz, A. S., Güngör, B., & Şahiner, N. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14010050 · Cited by 16
Molecular Docking and Network Pharmacology Interaction Analysis of Gingko Biloba (EGB761) Extract with Dual Target Inhibitory Mechanism in Alzheimer’s Disease
Singh, M., Jindal, D., Kumar, R., Pancham, P., Haider, S., Gupta, V., Mani, S., Rachana, R., Tiwari, R. K., & Chanda, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221222 · Cited by 17
Green synthesis of Kickxia elatine -induced silver nanoparticles and their role as anti-acetylcholinesterase in the treatment of Alzheimer’s disease
Huda, N. U., Ghneim, H. K., Fozia, F., Ahmed, M., Mushtaq, N., Sher, N., Khan, R. A., Ahmad, I., Al‐Sheikh, Y. A., Giesy, J. P., et al. (2023) · Green Processing and Synthesis · doi:10.1515/gps-2023-0060 · Cited by 15
Exploring the Potential of Antidiabetic Agents as Therapeutic Approaches for Alzheimer's and Parkinson's Diseases: A Comprehensive Review
Koshatwar, M., Acharya, S., Prasad, R., Lohakare, T., Wanjari, M. B., & Taksande, A. B. (2023) · Cureus · doi:10.7759/cureus.44763 · Cited by 15
Design, Synthesis, and Biological Evaluation of Ferulic Acid-Piperazine Derivatives Targeting Pathological Hallmarks of Alzheimer’s Disease
Singh, G., Kumar, S., Panda, S. R., Kumar, P., Rai, S., Verma, H., Singh, Y. P., Kumar, S., Srikrishna, S., Naidu, V. G. M., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00130 · Cited by 19
Initial Cholinesterase Inhibitor Therapy Dose and Serious Events in Older Women and Men
Rochon, P. A., Gruneir, A., Gill, S. S., Wu, W., Zhu, L., Herrmann, N., Bell, C. M., Austin, P. C., Stall, N. M., McCarthy, L. M., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15442 · Cited by 15
The food and medicinal values of indigenous leafy vegetables
Oboh, G., Oyeleye, S. I., & Ademiluyi, A. O. (2019) · Acta Horticulturae · doi:10.17660/actahortic.2019.1238.15 · Cited by 15
Synthesis, investigation of the cholinesterase inhibitory activities and in silico studies of some novel N-substituted phthalimide derivatives
Tan, A., & Almaz, Z. (2022) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-022-02492-0 · Cited by 15
Synthesis and anticholinesterase activity of fumaramide derivatives
Yerdelen, K. Ö., & Gul, H. I. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0493-8 · Cited by 15
Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer’s diseases therapy
Soltan, O. M., Abdelrahman, K. S., Bass, A. K. A., Takizawa, K., Narumi, A., & Konno, H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107651 · Cited by 14
Emerging pharmacological approaches for Huntington's disease
Singh, K., Jain, D., Sethi, P., Gupta, J. K., Tripathi, A. K., Kumar, S., Sarker, S. D., Nahar, L., & Guru, A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176873 · Cited by 15
Risk of Pneumonia in New Users of Cholinesterase Inhibitors for Dementia
Lai, E. C., Wong, M. B., Iwata, I., Zhang, Y., Hsieh, C., Yang, Y. K., & Setoguchi, S. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13380 · Cited by 14
Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent inhibitors of cholinesterases
Loesche, A., Wiese, J., Sommerwerk, S., Simon, V., Brandt, W., & Csük, R. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.051 · Cited by 14
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
Kakraba, S., Ayyadevara, S., Mainali, N., Balasubramaniam, M., Bowroju, S., Penthala, N. R., Atluri, R., Barger, S. W., Griffin, S. T., Crooks, P. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16101498 · Cited by 10
Profiling aducanumab as a treatment option for Alzheimer’s disease: an overview of efficacy, safety and tolerability
Thussu, S., Naidu, A., Manivannan, S., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2402058 · Cited by 14
Self-citation
Methoxy-naphthyl-Linked N ‑Benzyl Pyridinium Styryls as Dual Cholinesterase Inhibitors: Design, Synthesis, Biological Evaluation, and Structure–Activity Relationship
Abdullaha, M., Banoo, R., Nuthakki, V. K., Sharma, M. K., Kaur, S., Thakur, S., Kumar, A., Jadhav, H. R., & Bharate, S. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c08167 · Cited by 13
Synthesis, biochemical evaluation, and molecular modeling studies of aryl and arylalkyl di-n-butyl phosphates, effective butyrylcholinesterase inhibitors
Nakayama, K., Schwans, J. P., Sorin, E. J., Tran, T., Gonzalez, J. E., Arteaga, E. J., McCoy, S., & Alvarado, W. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.04.002 · Cited by 13
Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
Tsuno, N., Mori, T., Ishikawa, I., Bando, N., Park, H., Matsumoto, Y., Mori, I., Tanaka, M. H., Hirano, T., & Nakamura, Y. (2019) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.13644 · Cited by 13
Regulation of the Soluble Amyloid Precursor Protein α (sAPPα) Levels by Acetylcholinesterase and Brain-Derived Neurotrophic Factor in Lung Cancer Cell Media
Khashali, H. A., Ray, R., Coleman, K.-L., Atali, S., Haddad, B., Wareham, J., Guthrie, J. W., Heyl, D., & Evans, H. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810746 · Cited by 13
Rivastigmine and Parkinson dementia complex
Moretti, R., Torre, P., Vilotti, C., Antonello, R. M., & Pizzolato, G. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.6.817 · Cited by 13
Bacopa monnieri confers neuroprotection by influencing signaling pathways associated with interleukin 4, 13 and extracellular matrix organization in Alzheimer's disease: A proteomics-based perspective
Palollathil, A., Najar, M. A., Amrutha, S., Pervaje, R., Modi, P. K., & Prasad, T. S. K. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105864 · Cited by 12
Design and synthesis of new 1,2,3-triazole-methoxyphenyl-1,3,4-oxadiazole derivatives: selective butyrylcholinesterase inhibitors against Alzheimer’s disease
Iraji, A., Hariri, R., Hashempur, M. H., Ghasemi, M., Pourtaher, H., Saeedi, M., & Akbarzadeh, T. (2025) · BMC Chemistry · doi:10.1186/s13065-025-01475-5 · Cited by 12
Uncovering chemical profiles, biological potentials, and protection effect against ECM destruction in H2O2‐treated HDF cells of the extracts of Stachys tundjeliensis
Celep, İ. K., Zheleva‐Dimitrova, D., Sinan, K. I., Uba, A. İ., Nilofar, N., Mahomoodally, M. F., Aumeeruddy, M. Z., Çakılcıoğlu, U., Dall’Acqua, S., & Zengin, G. (2023) · Archiv der Pharmazie · doi:10.1002/ardp.202300528 · Cited by 12
Anticholinesterase Inhibition, Drug-Likeness Assessment, and Molecular Docking Evaluation of Milk Protein-Derived Opioid Peptides for the Control of Alzheimer’s Disease
Ji, D., Ma, J., Dai, J., Xu, M., Harris, P. W. R., Brimble, M. A., & Agyei, D. (2022) · Dairy · doi:10.3390/dairy3030032 · Cited by 11
Acetylcholinesterase inhibitors from Conocarpus lancifolius Engl. (Combretaceae)
Bar, F. M. A., Salkini, M. A., Amen, Y. M., & Sherif, A. E. (2022) · Natural Product Research · doi:10.1080/14786419.2022.2103124 · Cited by 11
Pyrimidine-morpholine hybrids as potent druggable therapeutics for Alzheimer’s disease: Synthesis, biochemical and in silico analyses
Zaib, S., Younas, M. T., Khan, I. A., Ali, H. S., McAdam, C. J., White, J. M., Jaber, F. T., Awwad, N. S., & Ibrahium, H. A. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106868 · Cited by 11
Demaghi, a polyherbal formulation, mitigates aluminum chloride-induced neurological impairment in mice: Insights from phytochemical analysis and behavioral assessment
Hassan, A., Usman, H., Ashraf, W., Alqahtani, F., Javaid, S., Siddique, F., Rasool, M. F., Imran, I., Ahmad, T., Rahman, A. M. A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21234 · Cited by 11
Role of Cytoskeletal Elements in Regulation of Synaptic Functions: Implications Toward Alzheimer’s Disease and Phytochemicals-Based Interventions
Verma, H., Kaur, S., Kaur, S., Gangwar, P., Dhiman, M., & Mantha, A. K. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04053-3 · Cited by 11
Some heterocycles connected to substituted piperazine by 1,3,4-oxadiazole linker: Design, synthesis, anticholinesterase and antioxidant activity
Kılıç-Kurt, Z., Konyar, D., Hayati, O. K. U. R., Kaplan, A., & Boğa, M. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139854 · Cited by 11
Current pharmacological treatments for neurodegenerative diseases
Shukla, A. K., Nilgirwar, P. S., & Bali, S. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00005-2 · Cited by 12
Synthesis, Molecular Docking and Molecular Dynamic Studies of Thiazolidineones as Acetylcholinesterase and Butyrylcholinesterase Inhibitors
Pavan, T. S., James, J. P., Dwivedi, P. S. R., Priya, S., Zakiya Fathima, C., & Sindhu, T. J. (2023) · Polycyclic aromatic compounds · doi:10.1080/10406638.2023.2233666 · Cited by 11
Detection by UPLC/ESI-TOF-MS of Alkaloids in Three Lycopodiaceae Species from French Polynesia and Their Anticholinesterase Activity
Ho, R., Marsousi, N., Eugster, P. J., Bianchini, J., & Raharivelomanana, P. (2009) · Natural Product Communications · doi:10.1177/1934578x0900401007 · Cited by 11
Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats
Karasová, J. Ž., Soukup, O., Korábečný, J., Hroch, M., Krejčiová, M., Hrabinová, M., Misík, J., Novotný, L., Hepnarová, V., & Kuča, K. (2019) · Drug and Chemical Toxicology · doi:10.1080/01480545.2019.1566350 · Cited by 11
Azole antifungal compounds could have dual cholinesterase inhibitory potential according to virtual screening, enzyme kinetics, and toxicity studies of an inhouse library
Barut, B., Sarı, S., Sabuncuoğlu, S., & Özel, A. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130268 · Cited by 11
In silico molecular docking analysis for potential anti-Alzheimer's compounds from the methanolic leaf extract of Erythroxylum monogynum using Gas chromatography–mass spectrometry
Subash, P., & Rao, K. S. (2021) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2021.101285 · Cited by 11

Authors: Grossberg, G. T.
Affiliations: Saint Louis University (US)
Corresponding author: Grossberg, George T
ORCID: Grossberg, George T
Venue: Current Therapeutic Research
Publisher: Elsevier BV
Published: 2003-04
Volume: 64
Issue: 4
Pages: 216-235
ISSN: 0011-393X (ISSN-L)
DOI: 10.1016/s0011-393x(03)00059-6
PMC: PMC4052996
OpenAlex: W170237590
Cited by: 384
References: 101
Citations by year: 2026: 26 · 2025: 45 · 2024: 72 · 2023: 41 · 2022: 28 · 2021: 27 · 2020: 20 · 2019: 24 · 2018: 19 · 2017: 14 · 2016: 11 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 5
FWCI: 3.00
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Current Therapeutic Research (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Novartis Pharma
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: cholinesterase inhibitors, Alzheimer's disease, donepezil, galantamine, rivastigmine, acetylcholinesterase inhibitors, butyrylcholinesterase inhibitors, dose escalation, safety and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks